Evidence map›Paper›PMID 29948559›Full record

ArticleDigestive diseases and sciences2018

Epstein-Barr Virus Antibody Titers Are Not Associated with Gastric Cancer Risk in East Asia.

Matthew G Varga, Hui Cai, Tim Waterboer, Gwen Murphy, Taichi Shimazu, Phil R Taylor, You-Lin Qiao, Sue K Park, Keun-Young Yoo, Sun Ha Jee and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Antibodies as biomarkers for cancer risk: a systematic review.Clinical and experimental immunology · 2022
    Pooled it
  2. Circulating Antibodies against Epstein-Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Pooled it
  3. Pooled it
  4. Article
  5. Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 4 countries.

Matthew G VargaDepartment of Epidemiology, Gillings School of Global Public Health and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 3207B Michael Hooker Research Center, Chapel Hill, NC, 27599, USA. matthew.varga@med.unc.edu.
Hui CaiDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37203, USA.
Tim WaterboerDivision of Molecular Diagnostics of Oncogenic Infections, Research Program in Infection, Inflammation, and Cancer, German Cancer Research Center (DFKZ), 69120, Heidelberg, Germany.
Gwen MurphyDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Taichi ShimazuEpidemiology and Prevention Group, National Cancer Center, Tokyo, 104-0045, Japan.
Phil R TaylorDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
You-Lin QiaoDepartment of Cancer Epidemiology, Chinese Academy of Medical Sciences and Peking Union Medial College, Beijing, 100021, China.
Sue K ParkDepartment of Biomedical Sciences, Cancer Research Institute, Seoul National University College of Medicine, Seoul, 110-799, Korea.
Keun-Young YooDepartment of Preventive Medicine, Seoul National University College of Medicine, Seoul, 110-799, Korea.
Sun Ha JeeDepartment of Epidemiology and Health Promotion, Institute for Health Promotion, Yonsei University, Seoul, 120-752, Korea.
Eo Rin ChoDepartment of Epidemiology and Health Promotion, Institute for Health Promotion, Yonsei University, Seoul, 120-752, Korea.
Jeongseon KimDivision of Cancer Epidemiology and Prevention, Research Institute, National Cancer Center, Goyang, 410-769, Korea.
Christian C AbnetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, 20892, USA.
Shoichiro TsuganeEpidemiology and Prevention Group, National Cancer Center, Tokyo, 104-0045, Japan.
Qiuyin CaiDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37203, USA.
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37203, USA.
Michael PawlitaDivision of Molecular Diagnostics of Oncogenic Infections, Research Program in Infection, Inflammation, and Cancer, German Cancer Research Center (DFKZ), 69120, Heidelberg, Germany.
Xiao-Ou ShuDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37203, USA.
Meira EppleinDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, 37203, USA.
Vanderbilt University Medical Center · USNational Cancer Institute · USGerman Cancer Research Center · DEKorea Health Promotion Institute · KRSeoul National University · KRChinese Academy of Medical Sciences & Peking Union Medical College · CNNational Cancer Center · KRUniversity of North Carolina at Chapel Hill · US

Funding

Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Cohort Study of Cancer inhibitory Factors in MenR01CA082729 · NCI · VANDERBILT UNIVERSITY · PI SHU, XIAO-OU · 2001 to 2011
$6.3M
Shanghai Womens Health StudyUM1CA182910 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ZHENG, WEI · 2014 to 2018
$5.9M
Shanghai Men's Health StudyUM1CA173640 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SHU, XIAO-OU · 2013 to 2017
$4.9M
Cancer Risk Reduction and Diet: A Cohort Study of WomenR37CA070867 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ZHENG, WEI · 2009 to 2013
$4.7M
Vanderbilt Training Program in Molecular and Genetic Epidemiology of CancerT32CA160056 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Xiao-Ou Shu · 2017 to 2026
$3.8M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
Helicobacter pylori blood biomarker for gastric cancer risk in East AsiaR01CA174853 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI EPPLEIN, MEIRA · 2013 to 2016
$2.3M
Vanderbilt Training Program in Molecular and Genetic Epidemiology of CancerR25CA160056 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HEIMBURGER, DOUGLAS CORBETT, SHU, XIAO-OU · 2012 to 2016
$2.1M
NCI NIH HHS 2T32CA057726-26NCI NIH HHS R01 CA082729NCI NIH HHS R01CA082729NCI NIH HHS R01 CA174853NCI NIH HHS R01CA174853NCI NIH HHS R25 CA160056NCI NIH HHS R25CA160056NCI NIH HHS R37 CA070867NCI NIH HHS R37CA070867NCI NIH HHS T32 CA057726NCI NIH HHS T32 CA160056NCI NIH HHS UM1 CA173640NCI NIH HHS UM1CA173640NCI NIH HHS UM1 CA182910NCI NIH HHS UM1CA182910NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

backgroundEpstein-Barr virus (EBV)-positive gastric cancers represent a distinct subtype of gastric cancers and account for nearly 10% of the gastric cancer burden, yet risk detection strategies for this cancer subtype are lacking.

methodsWe conducted a nested case-control study where we assayed 4 EBV antigens [viral capsid antigen (VCA), early antigen (EA), Epstein-Barr nuclear antigen (EBNA), and BZLF1-encoded replication activator protein (ZEBRA)] in either sera or plasma from 1447 gastric cancer cases and 1797 controls obtained from seven prospective cohorts representing individuals from the high gastric cancer-risk countries of China, Japan, and Korea.

resultsThe prevalence of EBV sero-positivity was universal with the exception of one sero-negative individual, and the highest titers of the EBV antigens VCA (OR 0.95, 95% CI 0.78-1.17), EBNA (OR 0.88, 95% CI 0.72-1.08), EA (OR 0.97, 95% CI 0.79-1.19), and ZEBRA (OR 0.87, 95% CI 0.71-1.07) were not associated with risk of incident gastric cancer. When we stratified these data by H. pylori status, there was no change in the association.

conclusionsMultiplex serology of the aforementioned EBV antigens in serum may not be a suitable biomarker for predicting gastric cancer risk in East Asian populations.

Indexed as

Epstein-Barr Virus InfectionsStomach NeoplasmsAntigens, ViralCase-Control StudiesFemaleHerpesvirus 4, HumanHumansJapanMaleMiddle AgedRepublic of KoreaRisk AssessmentSerologic TestsTumor Virus InfectionsAntigens, ViralEpstein–Barr virusGastric cancerMultiplex serology

Identifiers

PMID29948559
PMCPMC6139270
OpenAlexW2806820226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.